The Rationale for an Immunological Approach to Alzheimer's Therapeutics
Immunotherapy toward the Aβ peptide offers a unique therapeutic approach to the treatment of Alzheimer’s disease. The rationale is that antibodies interacting with the Aβ peptide will accelerate its clearance from the CNS, lead to less amyloid deposition, and reduce the other pathological features of Alzheimer’s disease. Evidence from transgenic mouse models of amyloid deposition is highly supportive of both pathological and functional benefits of this approach. Data from human trials of active immunization (using a vaccine to stimulate generation of antibodies) led to several apparent cases of autoimmune CNS inflammation.
KeywordsTg2576 Mouse Amyloid Deposition Amyloid Beta Passive Immunization Amyloid Beta Protein
Unable to display preview. Download preview PDF.
- Bard, F., Cannon, C., Barbour, R., Burke, R. L., Games, D., Grajeda, H., et al. (2000). Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nature Medicine, 6, 916–919.CrossRefPubMedGoogle Scholar
- Carty, N. C., Wilcock, D. M., Rosenthal, A., Grimm, J., Pons, J., Ronan, V., et al. (2006). Intracranial administration of deglycosylated C-terminal-specific anti-Abeta antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice. Journal of Neuroinflammation, 3, 11.CrossRefPubMedGoogle Scholar
- Li, Q., Cao, C., Chackerian, B., Schiller, J., Gordon, M., Ugen, K. E., et al. (2004). Overcoming antigen masking of anti-Abeta antibodies reveals breaking of B cell tolerance by virus-like particles in Abeta immunized amyloid precursor protein transgenic mice. BMC Neuroscience, 5, 21.CrossRefPubMedGoogle Scholar
- Morgan, D., Gordon, M. N., Tan, J., Wilcock, D., & Rojiani, A. M. (2005). Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer therapeutics. Journal of Neuropathology and Experimental Neurology, 64, 743–753.CrossRefPubMedGoogle Scholar
- Racke, M. M., Boone, L. I., Hepburn, D. L., Parsadainian, M., Bryan, M. T., Ness, D. K., et al. (2005). Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. Journal of Neuroscience, 25, 629–636.CrossRefPubMedGoogle Scholar
- Takeuchi, A., Irizarry, M. C., Duff, K., Saido, T. C., Hsiao, A. K., Hasegawa, M., et al. (2000). Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal loss. The American Journal of Pathology, 157, 331–339.PubMedGoogle Scholar
- Wilcock, D. M., Alamed, J., Gottschall, P. E., Grimm, J., Rosenthal, A., Pons, J., et al. (2006). Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. Journal of Neuroscience, 26, 5340–5346.CrossRefPubMedGoogle Scholar
- Wilcock, D. M., DiCarlo, G., Henderson, D., Jackson, J., Clarke, K., Ugen, K. E., et al. (2003). Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. Journal of Neuroscience, 23, 3745–3751.PubMedGoogle Scholar
- Wilcock, D. M., Rojiani, A., Rosenthal, A., Subbarao, S., Freeman, M. J., Gordon, M. N., et al. (2004). Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. Journal of Neuroinflammation, 1, 24.CrossRefPubMedGoogle Scholar